This analysis examines the historical and forecast performance for MedImmune in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark MedImmune's performance against key rivals in the ethical pharmaceutical sector See how MedImmune will build on its Synagis success with the launch of follow-on product Numax, which is set to drive growth over the forecast period Following the acquisition of MedImmune by AstraZeneca, evaluate the contribution to the Anglo-Swedish company's top-line figures from 2006 to 2012